GlycoMimetics, Inc. announced that the Phase 2 analysis of its adaptive Phase 2/3 study of uproleselan did not meet its primary endpoint. The study was conducted by the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology.
The trial evaluated uproleselan in adults aged 60 or older with newly diagnosed acute myeloid leukemia (AML) who were fit for intensive chemotherapy. The failure to meet the primary endpoint represents a significant setback for this specific clinical program.
This announcement pertains to a legacy asset from GlycoMimetics, the company that recently merged with Crescent Biopharma. The outcome of this study impacts the overall pipeline and strategic considerations for the combined entity, Crescent Biopharma.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.